BMY Stock Price Today (October 2026) — Bristol-Myers Squibb Company Analysis & Key Metrics 2026-10-20
Bristol-Myers Squibb Company (BMY) is trading at $61.68, up 4.84% today (as of October 2026). The stock continues to show mixed signals with a short-term dip within a broader uptrend, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $65.42 (6.1% upside).
- Volatility is moderate (32.83% annualized), implying notable price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (5.70% YoY) alongside competitive pressures in the Drug Manufacturers - General space.
BMY Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Bristol-Myers Squibb Company - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $159.98B
P/E Ratio
Forward P/E: 10.19
Revenue Growth
Year over Year
Analyst Target
+6.1% upside potential
Key Investor Questions About BMY
What investors need to know before buying
Based on current market data, BMY presents a neutral technical setup with mixed signals fundamentals.
- Technicals say: Neutral (RSI 56.24)
- Fundamentals say: Mixed signals (nuanced financial profile)
BMY's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for BMY investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $45.05B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, BMY stock traded between $42.52 and $68.64 and currently trades in the middle of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 32.83% annualized volatility and β=0.32, the stock exhibits low sensitivity to market moves—making BMY suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers (BMY) Has New Cancer Wins. Can They Offset the Patent Cliff?
Prothena's Partnership Strategy: Growth Driver or Limitation?
Bristol Myers vs. Eli Lilly: Is BMY’s Deep Valuation Discount Hiding an Opportunity?
Have $1,000 to Invest? This Dirt Cheap Pharma Stock Pays You 4.2% to Wait.
Latest TickZen Insights
All insights →No TickZen article on BMY yet. Our newest analysis:
Explore More Analysis for BMY
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 29, 2026 (before the open, usually)
Frequently Asked Questions
Common investor questions about Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (BMY) is currently trading at $61.68. The RSI (14-day) is at 56.2, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $65.42 implies 6.1% upside from current levels. Volatility is moderate at 32.8% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Bristol-Myers Squibb Company (BMY): The trailing P/E ratio is 14.12, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 10.19, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 2.37, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 5.87. Price-to-Sales is 2.66. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 24 analysts covering BMY, the consensus price target is $65.42. This represents a 6.1% upside from the current price of $61.68. The range spans from a low target of $41.00 to a high target of $82.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Bristol-Myers Squibb Company (BMY) pays a dividend with a current yield of approximately 4.45%. The annualized dividend rate is $2.51 per share. The payout ratio is 55.3%, which is moderate and suggests adequate earnings coverage for the dividend. The most recent ex-dividend date was Oct 2, 2026.
Key risks for Bristol-Myers Squibb Company (BMY) investors include: 1. Moderate volatility (32.8% annualized)—price swings are notable. 2. Elevated debt levels (debt-to-equity of 2.02x) which could pressure margins in a rising rate environment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Bristol-Myers Squibb Company's (BMY) current debt and financial health profile: Total debt stands at $45.05B. The debt-to-equity ratio is 2.02x, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 1.53, indicating strong short-term liquidity. The quick ratio is 1.29. The company holds $11.07B in cash and equivalents. Free cash flow is positive at $8.11B, providing a cushion for debt servicing and shareholder returns.